secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0001628280-22-027147
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics elects Dr. Thomas J. Lynch Jr. to Board of Directors
-------------------------------------------------------------------------

- Dr. Lynch appointed as Class I Director with term ending at 2024 annual meeting.
- Received option to purchase 32,000 shares vesting equally over three years.
- Appointed to the Science Committee of the Board.
- Compensation per non-employee director policy; indemnification agreement to be entered.
- No material transactions or arrangements with Dr. Lynch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022027147/0001628280-22-027147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022027147/fhtx-20221027.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer